About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Dallas | 17,468 Studies Near You | Clareo Health

Clinical Trials LocationsDallas

Clinical Trials in Dallas

Discover 17,468 clinical trials near Dallas, Texas. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 17181-17200 of 17,468 trials

COMPLETEDPhase 3< 1 mile

A Study to Assess the Safety and Effectiveness of Tacrolimus Cream in the Treatment of Psoriasis

NCT00293891

A study to assess the safety and effectiveness of tacrolimus cream in the treatment of psoriasis.

Astellas Pharma Inc658 participants

Birmingham, Alabama, United States • Little Rock, Arkansas, United States • San Diego, California, United States +30 more locations

COMPLETEDPhase 3< 1 mile

A Study to Assess the Safety and Effectiveness of Tacrolimus Cream in the Treatment of Psoriasis

NCT00293930

A study to assess the safety and effectiveness of tacrolimus cream in the treatment of psoriasis

Astellas Pharma Inc645 participants

Hot Springs, Arkansas, United States • San Diego, California, United States • San Francisco, California, United States +29 more locations

Find Trials by Condition in Dallas

Breast Cancerin Dallas Lung Cancerin Dallas Prostate Cancerin Dallas Colorectal Cancerin Dallas Melanomain Dallas Leukemiain Dallas Lymphomain Dallas Pancreatic Cancerin Dallas Ovarian Cancerin Dallas Brain Cancerin Dallas Diabetesin Dallas

Data from ClinicalTrials.govTerms

COMPLETEDPhase 3< 1 mile

Minocycline to Treat Amyotrophic Lateral Sclerosis

NCT00047723

The purpose of this trial is to test the safety, tolerability, and effectiveness of minocycline compared to placebo in patients with amyotrophic lateral sclerosis (ALS).

Amyotrophic Lateral Sclerosis

National Institute of Neurological Disorders and Stroke (NINDS)400 participantsStarted Jan 2003

Scottsdale, Arizona, United States • Irvine, California, United States • Los Angeles, California, United States +27 more locations

TERMINATEDPhase 3< 1 mile

Clinical Trial for Ovarian Cancer (OvaRex®)

NCT00050375

This study will compare the time to disease relapse between OvaRex® MAb-B43.13-treated patients and placebo-treated patients. This study will also compare assessments of survival, quality of life, immune response and safety between active and placebo groups.

Unither Pharmaceuticals354 participantsStarted Dec 2002

Huntsville, Alabama, United States • Phoenix, Arizona, United States • Little Rock, Arkansas, United States +59 more locations

COMPLETEDPhase 313 miles

Study Evaluating Combination of Levonorgestrel (LNG) and Ethinyl Estradiol (EE) in Premenstrual Dysphoric Disorder

NCT00128934

The purpose of this study is to determine whether levonorgestrel (LNG)/ethinyl estradiol (EE) is effective in treating the symptoms of severe premenstrual syndrome (PMS).

Menstruation DisturbancesPremenstrual Syndrome

Wyeth is now a wholly owned subsidiary of Pfizer744 participantsStarted Aug 2005

Scottsdale, Arizona, United States • Tucson, Arizona, United States • Jonesboro, Arkansas, United States +80 more locations

TERMINATEDPhase 318 miles

A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder.

NCT00267267

The Torcetrapib project was terminated on December 2, 2006 due to safety findings. Cholesterol levels will be measured over six weeks in subjects being treated with two different kinds of combination cholesterol medications to see how the different treatments compare to one another.

HyperlipidemiaDyslipidemia

Pfizer1,784 participantsStarted Jan 2006

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Chandler, Arizona, United States +120 more locations

COMPLETED31 miles

INSIGHTS ICD Registry

NCT00279968

The purpose of the Registry is to collect data on how Implantable Cardioverter Defibrillator (ICD) therapies and medications are being used by physicians to treat ventricular arrhythmias in order to better understand how to improve the clinical care of patients and effectiveness of ICD therapies.

Ventricular TachycardiaVentricular Fibrillation

Medtronic Cardiac Rhythm and Heart Failure1,326 participantsStarted Feb 2004

Little Rock, Arkansas, United States • Fountain Valley, California, United States • Poway, California, United States +41 more locations

COMPLETEDPhase 3182 miles

Study of Milnacipran for the Treatment of Fibromyalgia

NCT00098124

Antidepressants of all varieties represent a common form of therapy for many chronic states including fibromyalgia. The majority of antidepressants increase the levels of serotonin or norepinephrine in the central nervous system. Milnacipran is a dual norepinephrine and serotonin reuptake inhibitor and may be effective in the treatment of fibromyalgia.

Forest Laboratories1,200 participantsStarted Nov 2004

Birmingham, Alabama, United States • Mobile, Alabama, United States • Montgomery, Alabama, United States +77 more locations

COMPLETEDPhase 2190 miles

Study Evaluating the Safety and Efficacy of ERB-041 on Reduction of Symptoms Associated With Endometriosis in Reproductive-Aged Women

NCT00318500

The purpose of the study is to evaluate the efficacy and safety of two doses of ERB-041 (75 mg and 150 mg) relative to placebo on the relief of endometriosis-related symptoms (dysmenorrhea, pelvic pain, and deep dyspareunia) in reproductive aged women.

DysmenorrheaDyspareuniaEndometriosis+1 more

Wyeth is now a wholly owned subsidiary of Pfizer150 participantsStarted May 2006

Montgomery, Alabama, United States • Chandler, Arizona, United States • Phoenix, Arizona, United States +67 more locations

UNKNOWNPhase 3225 miles

Safety and Effectiveness of Cortical Stimulation in the Treatment of Stroke Patients With Upper Extremity Hemiparesis

NCT00170716

The purpose of this study is to assess the safety and effectiveness of cortical stimulation delivered concurrent with rehabilitation activities to enhance motor recovery in patients suffering from hemiparesis affecting the upper extremity following a stroke.

StrokeHemiparesis

Northstar Neuroscience174 participantsStarted Sep 2004

Tucson, Arizona, United States • Los Angeles, California, United States • San Francisco, California, United States +18 more locations

COMPLETEDPhase 3225 miles

Study Evaluating rFIX; BeneFIX in Severe Hemophilia B

NCT00037557

To characterize the safety and efficacy of rFIX in children less than 6 years of age with severe hemophilia B in the setting of acute bleeding episodes, prophylaxis, and/or surgery. This study will provide an opportunity for systematic observation of treatment with rFIX in children less than 6 years of age regardless of prior FIX treatment. Younger patients exhibit a different pharmacokinetic profile and therefore may respond differently to rFIX infusions when compared with older children and adults. This evaluation will provide data from which recommendations can be made regarding rFIX dosing and treatment of these patients. Surveillance for certain observations that have been made in patients treated with rFIX in the clinical and postmarketing setting will be performed, including inhibitor development, thrombogenicity, FIX recovery/lack of effect, allergic-type manifestations, and RBC agglutination. Comparisons will be derived from published reports and communications describing experience with other FIX products and protein therapeutics in general.

Wyeth is now a wholly owned subsidiary of Pfizer20 participantsStarted Sep 2002

Aurora, Colorado, United States • Detroit, Michigan, United States • New Brunswick, New Jersey, United States +3 more locations

COMPLETEDPhase 3225 miles

TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease

NCT00146211

This study is designed to determine the effect of 2 gram/day of ethyl-EPA on motor (movement) signs and symptoms of Huntington disease.

Huntington Disease

Amarin Neuroscience Ltd300 participantsStarted Sep 2005

Birmingham, Alabama, United States • Scottsdale, Arizona, United States • La Jolla, California, United States +38 more locations

COMPLETEDNA225 miles

Assessment of Inflammatory Mediators (AIM)

NCT00219895

Specific Aim: To determine whether neutrophils, active elastase, and cytokines measured in sputum induced using hypertonic saline are useful screening tests for determining if a particular agent with known anti-inflammatory properties is a suitable candidate for more extensive clinical trials in patients with CF. This aim will be addressed using an anti-inflammatory agent, ibuprofen, that has been shown to have clinical benefit in CF. A "no treatment" arm will be included as the control group.

Cystic Fibrosis

Ramsey, Bonnie, MD120 participantsStarted Aug 2004

Birmingham, Alabama, United States • Palo Alto, California, United States • San Diego, California, United States +13 more locations

COMPLETEDPhase 3225 miles

Efficacy, Tolerability and Safety of Dexmethylphenidate HCl Extended-Release Capsules in Children With Attention-Deficit/Hyperactivity Disorder

NCT00301236

The purpose of this study is to determine which dosages of dexmethylphenidate HCl extended-release capsules may represent effective treatment for ADHD in children 6-12 years of age.

Novartis252 participantsStarted Feb 2006

Mesa, Arizona, United States • Little Rock, Arkansas, United States • Los Angeles, California, United States +22 more locations

WITHDRAWNPhase 3420 miles

XERECEPT® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema

NCT00226668

The purpose of this study is to examine the safety and efficacy of XERECEPT (human Corticotropin-Releasing Factor, or hCRF) compared to dexamethasone in patients with primary malignant glioma who require increased dexamethasone doses to control symptom of peritumoral brain edema.

Brain EdemaBrain Tumor

Celtic Pharma Development Services120 participantsStarted Jan 2006

Phoenix, Arizona, United States • La Jolla, California, United States • Newport Beach, California, United States +23 more locations

COMPLETEDPhase 4548 miles

Trial to Assess the Shedding,Immunogenicity, and Safety of FluMist Administered to Healthy Individuals 5-49 Years of Age

NCT00192140

* To describe the proportion of individuals 5-49 years of age who shed vaccine strain viruses. * To describe the duration of shedding of vaccine viruses in individuals 5-49 years of age. * To describe the genotypic and phenotypic stability of shed vaccine viruses. * To describe the immune responses of FluMist in individuals 5-49 years of age. * To describe the safety of FluMist in individuals 5-49 years of age in relation to shedding and the immune response

MedImmune LLC345 participantsStarted Jun 2004

Miami, Florida, United States • Chicago, Illinois, United States • Bardstown, Kentucky, United States +8 more locations

TERMINATEDPhase 2677 miles

Study Evaluating GAP-486 on Heart Rhythm in Patients With Coronary Artery Disease

NCT00137332

The purpose of this study is to learn the effects of a test drug on heart rhythms, which may become life-threatening if left untreated, and to provide data to see if the drug is well tolerated and safe.

Wyeth is now a wholly owned subsidiary of Pfizer90 participantsStarted Nov 2005

Sacramento, California, United States • San Francisco, California, United States • Washington D.C., District of Columbia, United States +30 more locations

COMPLETEDPhase 2970 miles

A Study of CC-5013 in the Treatment of Complex Regional Pain Syndrome (CRPS)

NCT00067743

This is a multicenter, open-label study in adult subjects with Type 1 Complex Regional Pain Syndrome. Subjects diagnosed with unilateral Type 1 CRPS will be enrolled sequentially to receive CC-5013 10 mg/day orally. For each subject the study consists of two phases: Pre-treatment phase(1 wk) and treatment phase (12 wks)

Complex Regional Pain Syndrome (RSD)

Celgene Corporation40 participantsStarted Aug 2003

La Jolla, California, United States • Baltimore, Maryland, United States • Chapel Hill, North Carolina, United States +3 more locations

COMPLETEDPhase 3999 miles

The Study of Drotrecogin Alfa (Activated) in Adult Patients With Severe Sepsis at a Low Risk of Death

NCT00568737

Adult Patients with Severe Sepsis

Eli Lilly and Company2,640 participantsStarted Nov 2002

Haedi, Buenos Aires, Argentina • Monte Grande, Buenos Aires, Argentina • Rosario - Santa Fe, Buenos Aires, Argentina +67 more locations

COMPLETEDPhase 31100 miles

Effects in The ApoB/ApoA-I Ratio Using Rosuvastatin and Atorvastatin in Patients With Acute Coronary Syndrome

NCT00296387

The purpose of this study is to see if rosuvastatin compared to Atorvastatin is effective in treating ACS by decreasing the ApoB/ApoA-1 ratio and if starting statin within 24 h following the onset of the first symptoms is beneficial compared to placebo.

Acute Coronary Syndrome

AstraZeneca1,160 participantsStarted Jan 2006

Aalst, Belgium • Bonheiden, Belgium • Bouge, Belgium +99 more locations

PreviousPage 860 of 874Next

Heart Diseasein Dallas